Singapore markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4339+0.0032 (+0.74%)
At close: 04:00PM EDT
0.4156 -0.02 (-4.22%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 26.62M
Enterprise value -27.34M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)55.50
Price/book (mrq)1.61
Enterprise value/revenue -57.08
Enterprise value/EBITDA 0.56

Trading information

Stock price history

Beta (5Y monthly) 2.01
52-week change 3-66.36%
S&P500 52-week change 3-10.33%
52-week high 31.4000
52-week low 30.3500
50-day moving average 30.6299
200-day moving average 30.6857

Share statistics

Avg vol (3-month) 3272.88k
Avg vol (10-day) 31.17M
Shares outstanding 543.52M
Implied shares outstanding 6N/A
Float 828.07M
% held by insiders 15.42%
% held by institutions 149.52%
Shares short (14 Mar 2023) 4139.1k
Short ratio (14 Mar 2023) 41.76
Short % of float (14 Mar 2023) 40.42%
Short % of shares outstanding (14 Mar 2023) 40.32%
Shares short (prior month 14 Feb 2023) 4200.24k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Dec 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,730.58%

Management effectiveness

Return on assets (ttm)-71.65%
Return on equity (ttm)-150.19%

Income statement

Revenue (ttm)1.62M
Revenue per share (ttm)0.04
Quarterly revenue growth (yoy)14.10%
Gross profit (ttm)N/A
EBITDA -44.31M
Net income avi to common (ttm)-44.08M
Diluted EPS (ttm)-0.8900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.38M
Total cash per share (mrq)0.31
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)1.94
Book value per share (mrq)0.24

Cash flow statement

Operating cash flow (ttm)-40.61M
Levered free cash flow (ttm)-24.82M